Cochrane · systematic review · CD004437
Thrombolytic therapy for pulmonary embolism
Zuo, Z, Yue, J, Dong, BR, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
4
current version
GRADE rated
4
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 3 · 75%Moderate 1 · 25%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyThrombolytic therapy versus heparin: primary outcome measures for pulmonary embolism
Population: people with acute PE
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Death from all causes (duration of Thrombolytic therapy vs heparin: primary outcome measures | OR 0.58 [0.38, 0.88] | 19 studies · 2319 participants | Low Downgraded: risk of bias |
Recurrence of pulmonary emboli (duration of Thrombolytic therapy vs heparin: primary outcome measures | OR 0.54 [0.32, 0.91] | 12 studies · 2050 participants | Low Downgraded: risk of bias |
Major haemorrhagic events (duration of Thrombolytic therapy vs heparin: primary outcome measures | OR 2.84 [1.92, 4.2] | 15 studies · 2101 participants | Moderate Downgraded: risk of bias |
Minor haemorrhagic events (duration of Thrombolytic therapy vs heparin: primary outcome measures | OR 2.97 [1.66, 5.3] | 13 studies · 1757 participants | Low Downgraded: risk of bias, inconsistency |
Thrombolytic therapy versus heparin: primary outcome measures for pulmonary embolism
Population: patients with acute pulmonary embolism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes (duration of Thrombolytic therapy vs heparin: primary outcome measures | no estimate extracted | NR | No studies |
Death from all causes Thrombolytic therapy vs heparin: primary outcome measures | OR 0.57 [0.37, 0.87] | 17 studies · 2167 participants | Low Downgraded: risk of bias |
Recurrence of pulmonary emboli Thrombolytic therapy vs heparin: primary outcome measures | OR 0.51 [0.29, 0.89] | 10 studies · 1898 participants | Low Downgraded: risk of bias |
Major haemorrhagic events Thrombolytic therapy vs heparin: primary outcome measures | OR 2.9 [1.95, 4.31] | 12 studies · 1897 participants | Low Downgraded: risk of bias |
Minor haemorrhagic events Thrombolytic therapy vs heparin: primary outcome measures | OR 3.03 [1.6, 5.73] | 10 studies · 1553 participants | Very low Downgraded: risk of bias, inconsistency |
Thrombolytic therapy versus heparin: primary outcome measures for pulmonary embolism
Population: patients with acute pulmonary embolism
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Outcomes (Duration of Thrombolytic therapy vs heparin: primary outcome measures | no estimate extracted | NR | No studies |
Death from all causes Thrombolytic therapy vs heparin: primary outcome measures | OR 0.57 [0.37, 0.87] | 17 studies · 2167 participants | Low Downgraded: risk of bias |
Recurrence of pulmonary emboli Thrombolytic therapy vs heparin: primary outcome measures | OR 0.51 [0.29, 0.89] | 10 studies · 1898 participants | Low Downgraded: risk of bias |
Major haemorrhagic events Thrombolytic therapy vs heparin: primary outcome measures | OR 2.9 [1.95, 4.31] | 12 studies · 1897 participants | Low Downgraded: risk of bias |
Minor haemorrhagic events Thrombolytic therapy vs heparin: primary outcome measures | OR 3.03 [1.6, 5.73] | 10 studies · 1553 participants | Very low Downgraded: risk of bias, inconsistency |